Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
Merck Sharp & Dohme LLC
Shukui Qin; Zhendong Chen; Weijia Fang; Zhenggang Ren; Ruocai Xu; Baek-Yeol Ryoo; Zhiqiang Meng; Yuxian Bai; Xiaoming Chen; Xiufeng Liu; Juxiang Xiao; Gwo Fuang Ho; Yimin Mao; Xin Wang; Jieer Ying; Jianfeng Li; Wenyan Zhong; Yu Zhou; Abby B Siegel; Chunyi Hao